Background: Alzheimer's disease (AD) is characterized by presenting a
complex pathology, not fully resolved yet. This fact, together with the lack
of reliable models, has impeded the development of effective therapies.
Recently, several studies have shown that functional glial cell defects have
a key role in the pathology of AD. However, this glial dysfunction,
currently, cannot be correctly modeled using the available animal models,
so we hypothesized that cells derived from Alzheimer's patients can serve as
a better platform for studying the disease. In this sense, human pluripotent
stem cells (hPSC) allow the generation of different types of neural cells,
which can be used for disease modeling, identification of new targets and
drugs development.
Methods: We have a collection of hiPSCs derived from patients with
sporadic forms of AD stratified based on APOE genotype. We have
differentiated these cells towards neural cells and mature them to neurons or
astrocytes using a serum-free approach, to assess intrinsic differences
between those derived from AD patients or healthy controls.
Results: We have implemented a serum-free approach and generated
neural precursors and astrocytes from all the lines tested. We observe
differences at the phenotypic level and a reduced capacity to differentiate
towards neural lineage in those lines derived from APOE4 carriers.
Conclusions: Our preliminary data suggest intrinsic differences in the
neural differentiation capacity between cell lines derived from APOE4 or
APOE3 carrier subjects. Further experiments would contribute to elucidate
novel pathogenic pathways associated with neurodegeneration and
susceptible of therapeutic modulation, likely contributing to the
development of new effective drugs against AD.Acknowledgments:
This study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, cofinanced
by FEDER funds from European Union, through grants PI21/00915 (to
AG) and PI21/00914 (to JV); by Junta de Andalucia through Consejería de
Economía y Conocimiento grants PY18-RT-2233 (to AG) and US-1262734 (to JV)
co-financed by Programa Operativo FEDER 2014-2020, Consejeria de Salud grant
PI-0276-2018 (to JAGL) and Programa Operativo de Empleo Juvenil SNGJ4-11 to
LCP.
Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech